title: Risk of Parkinson's disease after tamoxifen treatment.
abstract: BACKGROUND
  Women have a reduced risk of developing Parkinson's disease (PD) compared with age-matched men. Neuro-protective effects of estrogen potentially explain this difference. Tamoxifen, commonly used in breast cancer treatment, may interfere with the protective effects of estrogen and increase risk of PD. We compared the rate of PD in Danish breast cancer patients treated with tamoxifen to the rate among those not treated with tamoxifen.
  
  
  METHODS
  A cohort of 15,419 breast cancer patients identified from the Danish Breast Cancer Collaborative Group database was linked to the National Registry of Patients to identify PD diagnoses. Overall risk and rate of PD following identification into the study was compared between patients treated with tamoxifen as adjuvant hormonal therapy and patients not receiving tamoxifen. Time-dependent effects of tamoxifen treatment on PD rate were examined to estimate the likely induction period for tamoxifen.
  
  
  RESULTS
  In total, 35 cases of PD were identified among the 15,419 breast cancer patients. No overall effect of tamoxifen on rate of PD was observed (HR = 1.3, 95% CI: 0.64-2.5), but a PD hazard ratio of 5.1 (95% CI: 1.0-25) was seen four to six years following initiation of tamoxifen treatment.
  
  
  CONCLUSIONS
  These results provide evidence that the neuro-protective properties of estrogen against PD occurrence may be disrupted by tamoxifen therapy. Tamoxifen treatments may be associated with an increased rate of PD; however these effects act after four years, are of limited duration, and the adverse effect is overwhelmed by the protection against breast recurrence conferred by tamoxifen therapy.
authors.affiliation: Department of Neurology, Boston University School of Medicine, 85 East Concord Street, Boston, MA 02118, USA. jlatoure@bu.edu
authors.forename: Jeanne C
authors.initials: JC
authors.lastname: Latourelle
authors.forename: Merete
authors.initials: M
authors.lastname: Dybdahl
authors.forename: Anita L
authors.initials: AL
authors.lastname: Destefano
authors.forename: Richard H
authors.initials: RH
authors.lastname: Myers
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Lash
mesh_terms: D017677:Age Distribution; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000209:etiology*; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen
references.citation: Neurology. 1999 Apr 22;52(7):1417-21
references.pmid: 10227628
references.citation: Acta Oncol. 2008;47(4):506-24
references.pmid: 18465317
references.citation: Synapse. 2000 Sep 15;37(4):245-51
references.pmid: 10891861
references.citation: Clin Neuropharmacol. 2007 Sep-Oct;30(5):276-80
references.pmid: 17909305
references.citation: Dan Med Bull. 1999 Jun;46(3):263-8
references.pmid: 10421985
references.citation: J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
references.pmid: 2841426
references.citation: Acta Oncol. 2008;47(4):497-505
references.pmid: 18465316
references.citation: Mov Disord. 2005 Feb;20(2):181-9
references.pmid: 15468111
references.citation: Exp Biol Med (Maywood). 2006 May;231(5):514-21
references.pmid: 16636299
references.citation: Histopathology. 2008 Jan;52(1):82-90
references.pmid: 18171419
references.citation: Cancer Detect Prev. 2007;31(5):384-90
references.pmid: 18023540
references.citation: Lancet. 2001 Mar 17;357(9259):871-2
references.pmid: 11265968
references.citation: Annu Rev Neurosci. 2003;26:81-104
references.pmid: 12574495
references.citation: Neurology. 1999 Apr 12;52(6):1214-20
references.pmid: 10214746
references.citation: Mov Disord. 1997 Nov;12(6):849-54
references.pmid: 9399205
references.citation: Oncologist. 2007 May;12(5):505-9
references.pmid: 17522235
references.citation: J Clin Oncol. 2007 Dec 20;25(36):5815-24
references.pmid: 17893378
references.citation: Rev Endocr Metab Disord. 2007 Sep;8(3):229-39
references.pmid: 17440819
references.citation: Mov Disord. 2001 Sep;16(5):830-7
references.pmid: 11746612
references.citation: Neurology. 1999 Jul 13;53(1):91-5
references.pmid: 10408542
references.citation: Neurosci Lett. 2007 Apr 24;417(1):95-9
references.pmid: 17398000
references.citation: Acta Oncol. 2003;42(3):179-85
references.pmid: 12852693
references.citation: Breast Cancer Res Treat. 2005 Aug;92(3):199-206
references.pmid: 16155790
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: Mov Disord. 2009 Jul 15;24(9):1359-65
references.pmid: 19424986
references.citation: Arch Neurol. 2004 Jun;61(6):886-8
references.pmid: 15210525
references.citation: J Occup Environ Med. 2005 May;47(5):466-72
references.pmid: 15891525
references.citation: Am J Epidemiol. 2004 Nov 15;160(10):977-84
references.pmid: 15522854
references.citation: Neuroscience. 2001;103(2):385-94
references.pmid: 11246153
references.citation: J Natl Cancer Inst Monogr. 2001;(30):56-61
references.pmid: 11773293
references.citation: J Natl Cancer Inst. 2006 Oct 4;98(19):1406-15
references.pmid: 17018787
references.citation: Neurology. 2004 Jun 8;62(11):2010-4
references.pmid: 15184606
references.citation: Neurotox Res. 2001 Jul;3(3):291-300
references.pmid: 15111254
references.citation: Neurology. 2003 Mar 11;60(5):790-5
references.pmid: 12629235
references.citation: J Neurocytol. 2000 May-Jun;29(5-6):387-99
references.pmid: 11424955
references.citation: J Natl Cancer Inst. 2001 Oct 3;93(19):1449-57
references.pmid: 11584060
references.citation: Neurology. 2005 Aug 9;65(3):383-90
references.pmid: 16087902
references.citation: Arch Neurol. 2007 Jul;64(7):990-7
references.pmid: 17620489
references.citation: Br J Cancer. 2005 Jan 17;92(1):201-5
references.pmid: 15583688
references.citation: Brain Res Mol Brain Res. 1999 Nov 10;73(1-2):119-28
references.pmid: 10581405
references.citation: Mov Disord. 2006 Aug;21(8):1221-5
references.pmid: 16671076
references.citation: Neuroreport. 2000 Feb 7;11(2):343-6
references.pmid: 10674483
references.citation: Ann Neurol. 2002 Sep;52(3):276-84
references.pmid: 12205639